NanoNeurosciences develops peptide-based nanomedicines to treat ophthalmological and neurological disorders by promoting cell survival and enhancing bioenergetics. Their proprietary platform delivers therapeutic payloads to affected cells, aiming to preserve vision and slow neurodegeneration for conditions like glaucoma, epilepsy, and depression.
Funding
Funding not disclosed
Founders
Product
Problem
Ophthalmological and neurological disorders, such as glaucoma, epilepsy, and depression, often lack effective treatments that address the root causes of cellular degeneration and dysfunction. Existing therapeutic approaches may only manage symptoms or offer limited long-term efficacy, leaving patients with progressive disease and reduced quality of life.
Solution
NanoNeurosciences develops nonsurgical, long-lasting nanomedicines designed to promote cell survival and enhance bioenergetics for treating ocular and neurological conditions. The company's proprietary platform utilizes advanced peptide-based nanocarriers that act as receptor agonists, stimulating critical cell survival pathways and optimizing mitochondrial function. These nanocarriers deliver therapeutic payloads directly to affected cells, reducing oxidative stress and restoring cellular balance. This science-driven approach aims to preserve vision, slow neurodegeneration, and provide novel therapeutic options for conditions like primary open-angle glaucoma (POAG), temporal lobe epilepsy (TLE), and major depressive disorder (MDD).
Target Audience
The primary target audience includes pharmaceutical companies and biotechnology firms focused on developing novel therapeutics for neurodegenerative and ophthalmological diseases, as well as clinical researchers and healthcare providers seeking advanced treatment options.
Features
- Peptide-based nanomedicines engineered as receptor agonists to activate cell survival and bioenergetic pathways.
- Proprietary supramolecular nanostructures utilizing lipopeptides (LPs) and amphiphilic small molecules (ASMs) for enhanced stability and controlled release.
- Targeted delivery of therapeutic payloads to specific ocular tissues and neural circuits, minimizing off-target effects.
- Optimization of mitochondrial function and reduction of oxidative stress to improve cellular energy and balance.
- Development pipeline includes candidates targeting NTSR1 receptors for POAG, SST2 receptors for MDD and TLE.
- Advanced laboratory capabilities including peptide synthesis, molecular biology tools, and high-precision imaging for R&D.
- Access to world-class nanomaterial characterization facilities through university partnerships.